The Somatic Genomic Landscape of Glioblastoma

We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer.

Citing Articles

Clinical Impact of a Next-Generation Sequencing Approach for Glioblastoma Patients.

Vivancos Sanchez C, Esteban Rodriguez M, Pelaez Garcia A, Taravilla-Loma M, Rodriguez-Dominguez V, Rodriguez-Antolin C Cancers (Basel). 2025; 17(5).

PMID: 40075591 PMC: 11898826. DOI: 10.3390/cancers17050744.

The spectrum of radiation therapy options for craniopharyngioma: a systematic review.

Harary P, Rajaram S, Hori Y, Park D, Chang S J Neurooncol. 2025; .

PMID: 40063185 DOI: 10.1007/s11060-025-05001-4.

A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma.

Ellingson B, Okobi Q, Chong R, Plawat R, Zhao E, Gafita A Neurooncol Adv. 2025; 7(1):vdaf022.

PMID: 40051661 PMC: 11883343. DOI: 10.1093/noajnl/vdaf022.

ATXN3 deubiquitinates ZEB1 and facilitates epithelial-mesenchymal transition in glioblastoma.

Wei R, Shi X, Qiu W, Yang M, Chen Y, Song S Sci Rep. 2025; 15(1):7868.

PMID: 40050358 PMC: 11885642. DOI: 10.1038/s41598-025-92317-w.

Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.

Breves S, Di Giammartino D, Nicholson J, Cirigliano S, Mahmood S, Lee U bioRxiv. 2025; .

PMID: 40034649 PMC: 11875237. DOI: 10.1101/2024.12.20.629544.

References

Tay Y, Kats L, Salmena L, Weiss D, Tan S, Ala U . Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011; 147(2):344-57. PMC: 3235920. DOI: 10.1016/j.cell.2011.09.029. View

Zheng S, Fu J, Vegesna R, Mao Y, Heathcock L, Torres-Garcia W . A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev. 2013; 27(13):1462-72. PMC: 3713427. DOI: 10.1101/gad.213686.113. View

Szerlip N, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y . Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A. 2012; 109(8):3041-6. PMC: 3286976. DOI: 10.1073/pnas.1114033109. View

Zheng S, Houseman E, Morrison Z, Wrensch M, Patoka J, Ramos C . DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol. 2011; 13(3):280-9. PMC: 3064601. DOI: 10.1093/neuonc/noq190. View

Hodis E, Watson I, Kryukov G, Arold S, Imielinski M, Theurillat J . A landscape of driver mutations in melanoma. Cell. 2012; 150(2):251-63. PMC: 3600117. DOI: 10.1016/j.cell.2012.06.024. View

Dolecek T, Propp J, Stroup N, Kruchko C . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012; 14 Suppl 5:v1-49. PMC: 3480240. DOI: 10.1093/neuonc/nos218. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Ichimura K, Pearson D, Kocialkowski S, Backlund L, Chan R, Jones D . IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009; 11(4):341-7. PMC: 2743214. DOI: 10.1215/15228517-2009-025. View

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

10.

Singh D, Chan J, Zoppoli P, Niola F, Sullivan R, Castano A . Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012; 337(6099):1231-5. PMC: 3677224. DOI: 10.1126/science.1220834. View

11.

Snuderl M, Fazlollahi L, Le L, Nitta M, Zhelyazkova B, Davidson C . Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011; 20(6):810-7. DOI: 10.1016/j.ccr.2011.11.005. View

12.

Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R . Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. Mod Pathol. 2009; 22(12):1600-11. DOI: 10.1038/modpathol.2009.132. View

13.

Bady P, Sciuscio D, Diserens A, Bloch J, van den Bent M, Marosi C . MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012; 124(4):547-60. PMC: 3444709. DOI: 10.1007/s00401-012-1016-2. View

14.

Sanborn J, Salama S, Grifford M, Brennan C, Mikkelsen T, Jhanwar S . Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. Cancer Res. 2013; 73(19):6036-45. PMC: 3800429. DOI: 10.1158/0008-5472.CAN-13-0186. View

15.

Vivanco I, Robins H, Rohle D, Campos C, Grommes C, Nghiemphu P . Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012; 2(5):458-71. PMC: 3354723. DOI: 10.1158/2159-8290.CD-11-0284. View

16.

Park S, Lee J, Ha M, Nam J, Kim V . miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2008; 16(1):23-9. DOI: 10.1038/nsmb.1533. View

17.

Carter S, Cibulskis K, Helman E, McKenna A, Shen H, Zack T . Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012; 30(5):413-21. PMC: 4383288. DOI: 10.1038/nbt.2203. View

18.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

19.

Inda M, Bonavia R, Mukasa A, Narita Y, Sah D, Vandenberg S . Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010; 24(16):1731-45. PMC: 2922502. DOI: 10.1101/gad.1890510. View

20.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View